Nanoparticle-in-Microparticle Delivery Systems (NiMDS): Production, administration routes and clinical potential

Journal of Biomaterials and Tissue Engineering

Volumn 3, Issue 1, 2013, Pages 22-38

  Imperiale, Julieta C ^a   Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Burst effect control; Drug targeting; Nanoparticle in Microparticle Delivery Systems; Release kinetics fine tuning

Indexed keywords

ACETYLSALICYLIC ACID; CHITOSAN; DICLOFENAC; DIPALMITOYLPHOSPHATIDYLCHOLINE; ENHANCED GREEN FLUORESCENT PROTEIN; ETHYL CELLULOSE; EUDRAGIT; IBUPROFEN; INDINAVIR; INTERLEUKIN 10; LACTOSE; LECTIN; MANNITOL; NANOPARTICLE; NUCLEIC ACID; PEPTIDES AND PROTEINS; POLYGLACTIN; POLYLACTIC ACID; RIFAMPICIN; TRIPTORELIN; TUMOR NECROSIS FACTOR ALPHA;

AREA UNDER THE CURVE; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL ADHESION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TARGETING; HUMAN; LIPOPHILICITY; MICROENCAPSULATION; MICROPARTICLE DELIVERY SYSTEM; NONHUMAN; PARTICLE SIZE; RADIOACTIVITY; RETICULOENDOTHELIAL SYSTEM; REVIEW; TISSUE REGENERATION;

EID: 84891613373     PISSN: 21579083     EISSN: 21579091     Source Type: Journal    
DOI: 10.1166/jbt.2013.1064     Document Type: Review

References (188)

1. K. Fu, R. Harrell, K. Zinski, C. Um, A. Jaklenec, J. Frazier, N. Lotan, P. Burke, A. M. Klibanov, and R. Langer, A potential approach for decreasing the burst effect of protein from PLGA microspheres. J. Pharm. Sci. 92, 1582 (2003).
2. C. Dong and J. A. Rogers, Acacia-gelatin microencapsulated liposomes: preparation, stability, and release of acetylsalicylic acid. Pharm. Res. 10, 141 (1993).
3. I. M. El-Sherbiny and H. D. Smyth, Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) selfassembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int. J. Pharm. 395, 132 (2010).
4. F. Q. Li, R. R. Ji, X. Chen, B. M. You, Y. H. Pan, and J. C. Su, Cetirizine dihydrochloride loaded microparticles design using ionotropic cross-linked chitosan nanoparticles by spray-drying method. Arch. Pharm. Res. 33, 1967 (2010).
5. C. Kriegel and M. M. Amiji, Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease. Clin. Transl. Gastroenterol. 2, e2 (2011).
6. K. Dharmala, J. W. Yoo, and C. H. Lee, Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J. Control Release 131, 190 (2008).
7. Y. Z. Li, X. Sun, T. Gong, J. Liu, J. Zuo, and Z. R. Zhang, Inhalable microparticles as carriers for pulmonary delivery of thymopentinloaded solid lipid nanoparticles. Pharm. Res. 27, 1977 (2010).
8. Y. T. Yang, C. T. Chen, J. C. Yang, and T. Tsai, Spraydried microparticles containing polymeric micelles encapsulating hematoporphyrin. AAPS Journal 12, 138 (2010).
9. R. J. Stenekes, A. E. Loebis, C. M. Fernandes, D. J. Crommelin, and W. E. Hennink, Degradable dextran microspheres for the controlled release of liposomes. Int. J. Pharm. 214, 17 (2001).
10. N. O. Dhoot and M. A. Wheatley, Microencapsulated liposomes in controlled drug delivery: strategies to modulate drug release and eliminate the burst effect. J. Pharm. Sci. 92, 679 (2003).
11. V. DiTizio, C. Karlgard, L. Lilge, A. E. Khoury, M. W. Mittelman, and F. DiCosmo, Localized drug delivery using crosslinked gelatin gels containing liposomes: factors influencing liposome stability and drug release. J. Biomed. Mater. Res. 51, 96 (2000).
12. I. Takagi, H. Shimizu, and T. Yotsuyanagi, Application of alginate gel as a vehicle for liposomes. I. Factors affecting the loading of drug-containing liposomes and drug release. Chem. Pharm. Bull. 44, 1941 (1996).
13. S. A. Svarovsky, M. J. Gonzalez-Moa, M. D. Robida, A. Y. Borovkov, and K. Sykes, Self-Assembled Micronanoplexes for Improved Biolistic Delivery of Nucleic Acids. Mol. Pharm. 6, 1927 (2009).
14. M. K. Lai, C. Y. Chang, Y. W. Lien, and R. C. Tsiang, Application of gold nanoparticles to microencapsulation of thioridazine. J. Control Release 111, 352 (2006).
15. S. Simovic, P. Heard, H. Hui, Y. Song, F. Peddie, A. K. Davey, A. Lewis, T. Rades, and C. A. Prestidge, Dry hybrid lipidsilica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol. Pharm. 6, 861 (2009).
16. K. Hadinoto, P. Phanapavudhikul, Z. Kewu, and R. B. Tan, Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm. 333, 187 (2007).
17. K. Hadinoto, P. Phanapavudhikul, Z. Kewu, and R. B. Tan, Novel Formulation of Large Hollow Nanoparticles Aggregates as Potential Carriers in Inhaled Delivery of Nanoparticulate Drugs. Ind. Eng. Chem. Res. 45, 3697 (2006).
18. M. M. Arnold, E. M. Gorman, L. J. Schieber, E. J. Munson, and C. Berkland, NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control Release 121, 100 (2007).
19. C. Klingler, B. W. Muller, and H. Steckel, Insulin-micro-and nanoparticles for pulmonary delivery. Int. J. Pharm. 377, 173 (2009).
20. A. Z. Chen, Y. Li, F. T. Chau, T. Y. Lau, J. Y. Hu, Z. Zhao, and D. K. Mok, Microencapsulation of puerarin nanoparticles by poly(llactide) in a supercritical CO(2) process. Acta Biomater. 5, 2913 (2009).
21. F. Q. Li, Y. B. Fei, X. Chen, X. J. Qin, J. Y. Liu, Q. G. Zhu, and J. H. Hu, Anchoring of ulex europaeus agglutinin to chitosan nanoparticles-in-microparticles and their in vitro binding activity to bovine submaxillary gland mucin. Chem. Pharm. Bull. 57, 1045 (2009).
22. L. J. Peek, L. Roberts, and C. Berkland, Poly(D, L-lactide-coglycolide) Nanoparticle Agglomerates as Carriers in Dry Powder Aerosol Formulation of Proteins. Langmuir 24, 9775 (2008).
23. D. T. O'Hagan, Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34, 305 (1998).
24. S. S. Guterres, H. Fessi, G. Barratt, F. Puisieux, and J. P. Devissaguet, Poly (D, L-lactide) nanocapsules containing nonsteroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm. Res. 12, 1 (1995).
25. J. Price (ed.), Handbook of Pharmaceutical Excipients, The Pharmaceutical Press, London (2003).
26. M. D. Bhavsar and M. M. Amiji, Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control Release 119, 339 (2007).
27. M. D. Bhavsar, S. B. Tiwari, and M. M. Amiji, Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control Release 110, 422 (2006).
28. M. D. Bhavsar and M. M. Amiji, Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS Pharm. Sci. Tech. 9, 288 (2008).
29. C. Kriegel and M. Amiji, Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control Release 150, 77 (2011).
30. M. D. Bhavsar and M. M. Amiji, Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 15, 1200 (2008).
31. T. M. Allen and A. Chonn, Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223, 42 (1987).
32. A. Joshi, R. Keerthiprasad, R. D. Jayant, and R. Srivastava, Nanoin-micro alginate based hybrid particles. Carbohydr. Polym. 81, 790 (2010).
33. Y. Yeo and K. Park, Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch. Pharmacol. Res. 27, 1 (2004).
34. A. Sheikh Hassan, A. Sapin, A. Lamprecht, E. Emond, F. El Ghazouani, and P. Maincent, Composite microparticles with in vivo reduction of the burst release effect. Eur. J. Pharm. Biopharm. 73, 337 (2009).
35. T. Freytag, A. Dashevsky, L. Tillman, G. E. Hardee, and R. Bodmeier, Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J. Control Release 69, 197 (2000).
36. A. S. Hasan, M. Socha, A. Lamprecht, F. E. Ghazouani, A. Sapin, M. Hoffman, P. Maincent, and N. Ubrich, Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int. J. Pharm. 344, 53 (2007).
37. X. Huang and C. Brazel, On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Rel. 73, 121 (2001).
38. J. Wang, B. A. Wang, and S. P. Schwendeman, Characterization of the initial burst release of a model peptide from poly(D, L-lactideco-glycolide) microspheres. J. Control Release 82, 289 (2002).
39. O. L. Johnson and M. A. Tracy, Peptide and protein drug delivery, edited by E. Mathiowitz, John Wiley and Sons, USA (1999), pp. 816-832.
40. Y.-Y Yang, T.-S. Chung, and N. P. Ng, Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22, 231 (2001).
41. G. Jian, B. C. Thanoo, and P. P. DeLuca, Effect of osmotic pressure in the solvent extraction phase on BSA release profile from PLGA microspheres. Pharm. Dev. Technol. 7, 391 (2002).
42. R. A. Jain, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 21, 2475 (2000).
43. C. Wang, W. Ye, Y. Zheng, X. Liu, and Z. Tong, Fabrication of drug-loaded biodegradable microcapsules for controlled release by combination of solvent evaporation and layer-by-layer selfassembly. Int. J. Pharm. 338, 165 (2007).
44. C. Berkland, K. Kim, and D. W. Pack, PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 20, 1055 (2003).
45. B. Guiziou, D. J. Armstrong, P. N. Elliott, J. L. Ford, and C. Rostron, Investigation of in-vitro release characteristics of NSAID-loaded polylactic acid microspheres. J. Microencapsul. 13, 701 (1996).
46. A. Fernandez-Carballido, R. Herrero-Vanrell, I. T. Molina-Martinez, and P. Pastoriza, Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Int. J. Pharm. 279, 33 (2004).
47. C. J. Thompson, D. Hansford, S. Higgins, C. Rostron, G. A. Hutcheon, and D. L. Munday, Evaluation of ibuprofen-loaded microspheres prepared from novel copolyesters. Int. J. Pharm. 329, 53 (2007).
48. I. M. El-Sherbiny and H. D. Smyth, Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol. Pharm. 9, 269 (2012).
49. M. Hombreiro-Pérez, J. Siepmann, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier and P. Maincent, Nondegradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. J. Control Rel. 88, 413 (2003).
50. M. Jelvehgari, J. Barar, H. Valizadeh, and N. Heidari, Preparation and evaluation of poly (ε-caprolactone) nanoparticlesinmicroparticles by W/O/W emulsion method. Iran J. Basic Med. Sci. 13, 85 (2010).
51. W. D. Rhine, D. S. Hsieh, and R. Langer, Polymers for sustained macromolecule release: Procedures to fabricate reproducible delivery systems and control release kinetics. J. Pharm. Sci. 69, 265 (1980).
52. Y. Han, H. Tian, P. He, X. Chen, and X. Jing, Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system. Int. J. Pharm. 378, 159 (2009).
53. W. Al-Azzam, E. A. Pastrana, and K. Griebenow, Co-lyophilization of bovine serum albumin (bsa) with poly(ethylene glycol) improves efficiency of bsa encapsulation and stability in polyester microspheres by a solid-in-oil-in-oil technique. Biotechnol. Lett. 24, 1367 (2002).
54. W. T. Leach, D. T. Simpson, T. N. Val, E. C. Anuta, Z. Yu, R. O. Williams, 3rd, and K. P. Johnston, Uniform encapsulation of stable protein nanoparticles produced by spray freezing for the reduction of burst release. J. Pharm. Sci. 94, 56 (2005).
55. H. R. Costantino, L. Firouzabadian, K. Hogeland, C. C. Wu, C. Beganski, K. G. Carrasquillo, M. Cordova, K. Griebenow, S. E. Zale, and M. A. Tracy, Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm. Res. 17, 1374 (2000).
56. S. Sant, V. Nadeau, and P. Hildgen, Effect of porosity on the release kinetics of propafenone-loaded PEG-g-PLA nanoparticles. J. Control Release 107, 203 (2005).
57. A. Grenha, B. Seixo, and C. Remuñán-López, Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25, 427 (2005).
58. K. E. Lee, S. H. Cho, H. B. Lee, S. Y. Jeong, and S. H. Yuk, Microencapsulation of lipid nanoparticles containing lipophilic drug. J. Microencapsul. 20, 489 (2003).
59. H. Maeda, T. Nakagawa, N. Adachi, Y. Sakai, T. Yamamoto, and A. Matsuoka, Design of long-acting formulation of protein drugs with a double-layer structure and its application to rhG-CSF. J. Control Release 91, 281 (2003).
60. A. J. Thote, K. Ono, and R. B. Gupta (eds.), AIChE Annual Meeting, Conference Proceedings, Cincinnati, OH (2005), p. 8566.
61. S. Hua, H. Yang, and A. Wang, A pH-sensitive nanocomposite microsphere based on chitosan and montmorillonite with in vitro reduction of the burst release effect. Drug. Dev. Ind. Pharm. 36, 1106 (2010).
62. Y. Kakizawa, R. Nishio, T. Hirano, Y. Koshi, M. Nukiwa, M. Koiwa, J. Michizoe, and N. Ida, Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles. J. Control Release 142, 8 (2010).
63. A. J. Thote and R. B. Gupta, Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine 1, 85 (2005).
64. T. Ren, W. Yuan, H. Zhao, and T. Jin, Sustained-release polylactideco-glycolide microspheres loaded with pre-formulated protein polysaccharide nanoparticles. Micro and Nano Letters 6, 70 (2011).
65. M. Jelvehgari, J. Barar, H. Valizadeh, B. D. Loveymi, and M. Ziapour, Controlled-and modulated-release drug-delivery systems. Transaction on Nanotechnology 17, 79 (2010).
66. Y. W. Chien, Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and J. C. Boylan, Marcel Dekker, New York (1990), pp. 281-313.
67. S. Acharya and S. K. Sahoo, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug. Deliv. Rev. 63, 170 (2011).
68. J. S. Golub, Y. T. Kim, C. L. Duvall, R. V. Bellamkonda, D. Gupta, A. S. Lin, D. Weiss, W. R. Taylor, and R. E. Guldberg, Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am. J. Physiol. Heart. Circ. Physiol. 298, 1959 (2010).
69. D. Klose, F. Siepmann, K. Elkharraz, and J. Siepmann, PLGAbased drug delivery systems: importance of the type of drug and device geometry. Int. J. Pharm. 354, 95 (2008).
70. R. Bodmeier, K. H. Oh, and H. Chen, The effect of the addition of low molecular weight poly(dl-lactide) on drug release from biodegradable poly(dl-lactide) drug delivery systems. Int. J. Pharm. 51, 1 (1989).
71. J. K. Li, N. Wang, and X. S. Wu, A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J. Pharm. Sci. 86, 891 (1997).
72. J. C. Imperiale, D. A. Chiapetta, and A. Sosnik, Nuevos nanosistemas de liberación de drogas mucoadhesivos para la liberación sostenida de inhibidores de proteasa en el tratamiento de HIV, Proceedings of the XVIII Argentine Congress of Bioengineering, Mar del Plata, Argentina (2011).
73. Z. Li, P. Chen, X. Xu, X. Ye, and J. Wang, Preparation of chitosansodium alginate microcapsules containing ZnS nanoparticles and its effect on the drug release. Mat. Sci. Eng. C 29, 2250 (2009).
74. H. Lis and N. Sharon, Lectins as molecules and as tools. Annu. Rev. Biochem. 55, 35 (1986).
75. C. M. Lehr, J. A. Bouwstra, W. Kok, A. B. Noach, A. G. de Boer, and H. E. Junginger, Bioadhesion by means of specific binding of tomato lectin. Pharm. Res. 9, 547 (1992).
76. G. Ponchel and J. Irache, Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34, 191 (1998).
77. C. M. Lehr, Lectin-mediated drug delivery: the second generation of bioadhesives. J. Control Release 65, 19 (2000).
78. A. Sosnik, D. A. Chiappetta, and A. M. Carcaboso, Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J. Control Release 138, 2 (2009).
79. A. Sosnik, A. M. Carcaboso, R. J. Glisoni, M. A. Moretton, and D. A. Chiappetta, New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug. Del. Rev. 62, 547 (2010).
80. A. Sosnik and M. Amiji, Nanotechnology solutions for infectious diseases in developing nations. Preface. Adv. Drug Del. Rev. 62, 375 (2010).
81. A. Sosnik, Nanotechnology contributions to the pharmacotherapy of pediatric HIV: A dual scientific and ethical challenge and a still pending agenda. Nanomedicine-UK 5, 833 (2010).
82. A. Sosnik, K. P. Seremeta, J. C. Imperiale, and D. A. Chiappetta, Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Op. Drug Deliv. 9, 303 (2012).
83. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima, A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control Release 104, 337 (2005).
84. A. Kikuchi and T. Okano, Pulsatile drug release control using hydrogels. Adv. Drug Deliv. Rev. 54, 53 (2002).
85. S. Wee and W. R. Gombotz, Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31, 267 (1998).
86. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice, Controlled vaccine release in the gut-associated lynphoid tissue. I. Orally administered biodegradable microspheres target the Peyer's patches J. Control Release 11, 205 (1990).
87. R. Martien, B. Loretz, and A. B. Schnurch, Oral gene delivery: Design of polymeric carrier systems shielding toward intestinal enzymatic attack. Biopolymers 83, 327 (2006).
88. T. Mizoe, T. Ozeki, and H. Okada, Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J. Control Release 122, 10 (2007).
89. M. Tobio, J. Nolley, Y. Y. Guo, J. McIver, and M. J. Alonso, A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm. Res. 16, 682 (1999).
90. T. J. Carstensen, Modern Pharmaceutics, edited by G. S. Banker and C. T. Rhodes, Academic Press, New York (1973), Vol. 2, pp. 1-89.
91. J. L. Cleland, A. Daugherty, and R. Mrsny, Emerging protein delivery methods. Curr. Opin. Biotechnol. 12, 212 (2001).
92. R. Jalil and J. R. Nixon, Microencapsulation using poly (L-lactic acid) II: Preparative variables affecting microcapsule properties. J. Microencapsul. 7, 25 (1990).
93. Y. Wen, M. R. Gallego, L. F. Nielsen, L. Jorgensen, H. Everland, E. H. Møller, and H. M. Nielsen, Biodegradable nanocomposite microparticles as drug delivering injectable cell scaffolds. J. Control Release 156, 11 (2011).
94. H. J. Chung, I. K. Kim, T. G. Kim, and T. G. Park, Highly open porous biodegradable microcarriers: In vitro cultivation of chondrocytes for injectable delivery. Tissue Eng. A 14, 607 (2008).
95. Q. Hou, P. A. De Bank, and K. M. Shakesheff, Injectable scaffolds for tissue regeneration. J. Mater. Chem. 14, 1915 (2004).
96. J. S. Patton and R. M. Platz, Routes of delivery: Case studies: Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8, 179 (1992).
97. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke, The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2, 198 (2001).
98. H. M. Courrier, N. Butz, and T. F. Vandamme, Pulmonary drug delivery systems: recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems 19, 425 (2002).
99. M. Jalalipour, K. Gilani, H. Tajerzadeh, A. R. Najafabadi, and M. Barghi, Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int. J. Pharm. 352, 209 (2008).
100. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke, The lung as a route for systemic delivery of therapeutic proteins and peptides. Respiratory Research 2, 198 (2001).
101. D. A. Edwards, A. Ben-Jebria, and R. J. Langer, Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85, 379 (1998).
102. D. A. LaVan, T. McGuire, and R. Langer, Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21, 1184 (2003).
103. R. H. Hastings, H. G. Folkesson, and M. A. Matthay, Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung. Cell Mol. Physiol. 286, 679 (2004).
104. M. Duszyk, CFTR and lysozyme secretion in human airway epithelial cells. Eur. J. Physiol. 443, S45 (2001).
105. R. Fernández-Urrusuno, D. Romani, P. Calvo, J. L. Vila-Jato, and M. J. Alonso, Development of a freeze-dried formulation of insulinloaded chitosan nanoparticles intended for nasal administration. STP Pharm. Sci. 9, 429 (1999).
106. A. E. John, N. W. Lukacs, A. A. Berlin, A. Palecanda, R. F. Bargatze, L. M. Stoolman, and J. O. Nagy, Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease. J. FASEB 17, 2296 (2003).
107. M. Kumar, X. Kong, A. K. Behera, G. R. Hellermann, R. F. Lockey, and S. S. Mohapatra, Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genet. Vaccines Ther. 1, 3 (2003).
108. T. Mizoe, T. Ozeki, and H. Okada, Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS Pharm. Sci. Tech. Published online 18 June, 9, 755 (2008).
109. J. Wendorf, M. Singh, J. Chesko, J. Kazzaz, E. Soewanan, M. Ugozzoli, and D. O'Hagan, A practical approach to the use of nanoparticles for vaccine delivery. J. Pharm. Sci. 95, 2738 (2006).
110. S. Schurch, P. Gehr, V. I. Hof, M. Geiser, and F. Green, Surfactant displaces particles toward the epithelium in airways and alveoli. Resp. Physiol. 80, 17 (1990).
111. K. Makino, N. Yamamoto, K. Higuchi, N. Harada, H. Ohshima, and H. Terada, Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloid Surf. B 27, 33 (2003).
112. C. J. Musante, J. D. Schroeter, J. A. Rosati, T. M. Crowder, A. J. Hickey, and T. B. Martonen, Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci. 91, 1590 (2002).
113. J. N. Pritchard, The influence of lung deposition on clinical response. J. Aerosol. Med. 14, S19 (2001).
114. B. J. Lipworth, Targets for inhaled treatment. Respir. Med. 94, S13 (2000).
115. J. Heyder, J. Gebhart, G. Rudolf, C. F. Schiller, and W. Stahlhofen, Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J. Aerosol. Sci. 17, 811 (1986).
116. W. H. Finlay, K. W. Stapleton, and P. Zuberbuhler, Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J. Aerosol. Sci. 28, 1301 (1997).
117. W. H. Finlay and M. G. Gehmlich, Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int. J. Pharm. 210, 83 (2000).
118. A. Clark, Formulation of proteins and peptides for inhalation. Drug Deliv. Syst. Sci. 2, 73 (2002).
119. S. Bozdag, K. Dillen, J. Vandervoort, and A. Ludwig, The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D, L-lactide-glycolide) nanoparticles. J. Pharm. Pharmacol. 57, 699 (2005).
120. D. Quintanar-Guerrero, A. Ganem-Quintanar, E. Allemann, H. Fessi, and E. Doelker, Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D, L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J. Microencapsul. 15, 107 (1998).
121. L. A. Dailey, T. Schmehl, T. Gessler, M. Wittmar, F. Grimminger, W. Seeger, and T. Kissel, Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control Release 86, 131 (2003).
122. I. Gonda, Pharmaceutical Inhalation Aerosol Technology, Second edn., edited by A. J. Hickey, Targeting by Deposition, Informa Healthcare, USA (2003).
123. C. Bosquillon, C. Lombry, V. Préat, and R. Vanbever, Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control Release 70, 329 (2001).
124. G. Oberdörster, E. Oberdörster, and J. Oberdörster, Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823 (2005).
125. N. Y. Chew and H. K. Chan, Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 18, 1570 (2001).
126. H. Chrystyn, Is total particle dose more important than particle distribution? Resp. Med. 91, 17 (1997).
127. J. O. Sham, Y. Zhang, W. H. Finlay, W. H. Roa, and R. Löbenberg, Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269, 457 (2004).
128. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada, One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticlecontaining mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control Release 135, 19 (2009).
129. S. Al-Qadi, A. Grenha, and C. Remuñán-López, Microspheres loaded with polysaccharide nanoparticles for pulmonary delivery: Preparation, structure, and surface analysis. Carbohydr. Polym. 86, 25 (2011).
130. A. Grenha, C. I. Grainger, L. A. Dailey, B. Seijo, G. P. Martin, C. B. Remuñán-López, and B. Forbes Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur. J. Pharm. Sci. 31, 73 (2007).
131. G. Pilcer, F. Vanderbist, and K. Amighi, Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int. J. Pharm. 365, 162 (2009).
132. A. Grenha, C. Remuñán-López, E. L. S. Carvalho, and B. Seijo, Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur. J. Pharm. Biopharm. 69, 83 (2008).
133. N. Mohajel, A. R. Najafabadi, K. Azadmanesh, A. Vatanara, E. Moazeni, A. Rahimi, and K. Gilani, Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int. J. Pharm. 423, 577 (2012).
134. F. Ahsan, I. P. Rivas, M. A. Khan, and A. I. Suarez-Torres, Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release 79, 29 (2002).
135. J. B. Lyczak, C. L. Cannon, and G. B. Pier, Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15, 194 (2002).
136. D. L. French, D. A. Edwards, and R. W. Niven, The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol. Sci. 27, 769 (1996).
137. N. Tsapis, D. Bennett, B. Jackson, D. A. Weitz, and D. A. Edwards, Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U.S.A. 99, 12001 (2002).
138. S. M. McAllister, H. O. Alpar, Z. Teitelbaum, and D. B. Bennett, Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung? Adv. Drug Deliv. Rev. 19, 89 (1996).
139. J. Wan, J. B. Gordon, K. Muirhead, M. W. Hickey, and M. Coventry, Incorporation of nisin in micro-particles of calcium alginate. Lett. Appl. Microbiol. 24, 153 (1997).
140. Y. Y. Yang, T. S. Chung, and N. P. Ng, Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22, 231 (2001).
141. A. H. Kibbe (ed.), Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington and Pharmaceutical Press, London (2000).
142. A. Wade and P. J. Weller (eds.), Handbook of Pharmaceutical Excipients, Second edn., The Pharmaceutical Press, Washington DC (1994), pp. 186-190.
143. M. G. Moldenhauer and J. G. Nairn, Formulation parameters affecting the preparation and properties of microencapsulated ionexchange resins containing theophylline. J. Pharm. Sci. 8, 659 (1990).
144. W. Hennink, O. Franssen, W. van Dijk-Wolthuis, and H. Talsma, Dextran hydrogels for the controlled release of proteins. J. Control Rel. 48, 107 (1997).
145. K. Janes, P. Calvo, and M. Alonso, Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47, 83 (2001).
146. C. Freitas and R. H. Müller, Spray-drying of solid lipid nanoparticles (SLN TM). Eur. J. Pharm. Biopharm. 46, 145 (1998).
147. P. O. Souilliac, C. R. Middaugh, and J. H. Rytting, Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. Int. J. Pharm. 235, 207 (2002).
148. A. Grenha, B. Seijo, C. Serra, and C. Remuñán-López, Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules. 8, 2072 (2007).
149. N. V. Majeti and R. Kumar, A review of chitin and chitosan applications. React. Funct. Polym. 46, 1 (2000).
150. S. Cao, B. Liu, X. Deng, and S. Li, Core/shell particles containing 3-(methacryloxypropyl)-trimethoxysilane in the shell: synthesis, characterization, and applicati. Macromol. Biosci. 5, 669 (2005).
151. S. Koennings, A. Berie, J. Tessmar, T. Blunk, and A. Goepferich, Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. J. Control Release 119, 173 (2007).
152. S. Hirano, H. Seino, Y. Akiyama, and I. Nonaka, Biocompatibility of chitosan by oral and intravenous administrations. Polym. Mater. Sci. Eng. 59, 897 (1988).
153. M. Issa, M. Koping-Hoggard, and P. Artursson, Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov. Today: Technologies 2, 1 (2005).
154. F. Andrade, F. Goycoolea, D. A. Chiappetta, J. das Neves, A. Sosnik, and B. Sarmento, Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug delivery. Int. J. Carbohyd. Chem. Article ID 865704 (2011).
155. C. M. Lehr, J. A. Bouwstra, E. H. Schacht, and H. E. Junginger, In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymer. Int. J. Pharm. 78, 43 (1992).
156. S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, Recent advances on chitosan-based micro-and nanoparticles in drug delivery. Journal of Control Release 100, 5 (2004).
157. J. H. Park, S. Kwon, M. Lee, H. Chung, J. H. Kim, Y. S. Kim, R. W. Park, I. S. Kim, S. B. Seo, I. C. Kwon, and S. Y. Jeong, Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27, 119 (2006).
158. P. Artursson, T. Lindmark, S. S. Davisa, and L. Illum, Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358 (1994).
159. A. De Campos, A. Sánchez, and M. J. Alonso, Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224, 159 (2001).
160. G. Borchard, H. L. Lueszen, A. G. De Boer, J. C. Verhoef, C. M. Lehr, and H. E. Junginger, The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control Release 39, 131 (1996).
161. A. Portero, C. Remuñán-López, and H. M. Nielsen, The potential of chitosan in enhancing peptide and protein absorption across the TR146 cell culture model-an in vitro model of the buccal epithelium. Pharm. Res. 19, 169 (2002).
162. A. Bernkop-Schnürch, C. E. Kast, and D. Guggi, Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J. Control Release 93, 95 (2003).
163. R. A. Muzzarelli, Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell. Mol. Life Sci. 53, 131 (1997).
164. Z. Leonenko, M. Rodenstein, J. Dohner, L. M. Eng, and M. Amrein, Electrical surface potential of pulmonary surfactant. Langmuir 22, 10135 (2006).
165. T. S. Wiedmann, R. Bhatia, and L. W. Wattenberg, Drug solubilization in lung surfactant. J. Control Release 65, 43 (2000).
166. C. Evora, I. Soriano, R. A. Rogers, K. M. Shakesheff, J. Hanes, and R. Langer, Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control Release 51, 143 (1998).
167. B. G. Jones, P. A. Dickinson, M. Gumbleton, and I. W. Kellaway, Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383. J. Pharm. Pharmacol. 54, 1065 (2002).
168. D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer, Large porous particles for pulmonary drug delivery. Science 276, 1868 (1997).
169. H. Steckel and H. Brandes, A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 278, 187 (2004).
170. H. J. Chung, I. K. Kim, T. G. Kim, and T. G. Park, Highly Open Porous Biodegradable Microcarriers: In vitro Cultivation of Chondrocytes for Injectable Delivery. Tissue Eng. 14, 607 (2008).
171. S. Suarez, P. O'Hara, M. Kazantseva, C. E. Newcomer, R. Hopfer, D. N. McMurray, and A. J. Hickey, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm. Res. 18, 1315 (2001).
172. L. A. Dailey, N. Jekel, L. Fink, T. Gessler, T. Schmehl, M. Wittmar, T. Kissel, and W. Seeger, Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 215, 100 (2006).
173. V. R. Sinha, K. Bansal, R. Kaushik, R. Kumria, and A. Trehan, Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int. J. Pharm. 278, 1 (2004).
174. F. Wu and T. Jin, Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS Pharm. Sci. Tech. 9, 1218 (2009).
175. T. H. Lee, J. J. Wang, and C. H. Wang, Controlled release of Etanidazole from double-walled biodegradable microspheres. J. Control Release 83, 437 (2002).
176. Y. Yeo, N. Baek, and K. Park, Microencapsulation methods for delivery of protein drugs. Biotechnol. Bioproc. Eng. 6, 213 (2001).
177. V. Sluzky, J. A. Tamada, A. M. Klibanov, and R. Langer, Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. 88, 9377 (1991).
178. E. R. Johnson, L. A. Lanaski, V. Gupta, M. J. Griffin, H. T. Gaud, T. Needham, and H. Zia, Pharm. Res. 7, S-181 (1990).
179. E. Kai and T. Ochiya, A method for oral DNA delivery with N-acetylated chitosan. Pharm. Res. 21, 838 (2004).
180. E. Walter, M. A. Croyle, B. L. Davidson, B. J. Roessler, J. M. Hilfinger, and G. L. Amidon, Adenovirus mediated gene transfer to intestinal epithelial cells as a potential approach for oral delivery of peptides and proteins. J. Control Release 46, 75 (1997).
181. D. J. Glover, H. J. Lipps, and D. A. Jans, Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 6, 299 (2005).
182. C. W. Pouton and L. W. Seymour, Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev. 34, 3 (1998).
183. J. M. Dang and K. W. Leong, Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 58, 487 (2006).
184. D. R. Sorensen, M. Leirdal, and M. Sioud, Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327, 761 (2003).
185. Y. Zhang, P. Cristofaro, R. Silbermann, O. Pusch, D. Boden, T. Konkin, V. Hovanesian, P. R. Monfils, M. Resnick, S. F. Moss, and B. Ramratnam, Engineering mucosal RNA interference in vivo. Mol. Ther. 14, 336 (2006).
186. S. Lecollinet, F. Gavard, M. J. Havenga, O. B. Spiller, A. Lemckert, J. Goudsmit, M. Eloit, and J. Richardson, Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. J. Virol 80, 2747 (2006).
187. G. Romano, C. Pacilio, and A. Giordano, Gene transfer technology in therapy: current applications and future goals. Stem Cells 17, 191 (1999).
188. G. Han, C. T. Martin, and V. M. Rotello, Stability of gold nanoparticle-bound DNA toward biological, physical, and chemical agents. Chem. Biol. Drug Des. 67, 78 (2005).